Abstract:Background— Cardiotoxicity is a leading cause for drug attrition during pharmaceutical development and has resulted in numerous preventable patient deaths. Incidents of adverse cardiac drug reactions are more common in patients with preexisting heart disease than the general population. Here we generated a library of human induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs) from patients with various hereditary cardiac disorders to model differences in cardiac drug toxicity susceptibility for patients of different genetic backgrounds. Methods and Results— Action potential duration and drug-induced arrhythmia were measured at the single cell level in hiPSC-CMs derived from healthy subjects and patients with hereditary long QT syndrome, familial hypertrophic cardiomyopathy, and familial dilated cardiomyopathy. Disease phenotypes were verified in long QT syndrome, hypertrophic cardiomyopathy, and dilated cardiomyopathy hiPSC-CMs by immunostaining and single cell patch clamp. Human embryonic stem cell–derived cardiomyocytes (hESC-CMs) and the human ether-a-go-go –related gene expressing human embryonic kidney cells were used as controls. Single cell PCR confirmed expression of all cardiac ion channels in patient-specific hiPSC-CMs as well as hESC-CMs, but not in human embryonic kidney cells. Disease-specific hiPSC-CMs demonstrated increased susceptibility to known cardiotoxic drugs as measured by action potential duration and quantification of drug-induced arrhythmias such as early afterdepolarizations and delayed afterdepolarizations. Conclusions— We have recapitulated drug-induced cardiotoxicity profiles for healthy subjects, long QT syndrome, hypertrophic cardiomyopathy, and dilated cardiomyopathy patients at the single cell level for the first time. Our data indicate that healthy and diseased individuals exhibit different susceptibilities to cardiotoxic drugs and that use of disease-specific hiPSC-CMs may predict adverse drug responses more accurately than the standard human ether-a-go-go –related gene test or healthy control hiPSC-CM/hESC-CM screening assays.

Computational Screen for Sex-Specific Drug Effects in a Cardiac Fibroblast Network Model

Effects of the Fibroblast-Myocyte in Cardiac Electromechanical Coupling: A Preliminary Simulation Study

Drug Screening Using a Library of Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes Reveals Disease-Specific Patterns of Cardiotoxicity

Screening Drug-Induced Arrhythmia Using Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes and Low-Impedance Microelectrode Arrays

Large-scale in Silico Identification of Drugs Exerting Sex-Specific Effects in the Heart

Applications for Induced-Pluripotent Stem Cell Derived-Cardiomyocytes

A Biomimetic Optical Cardiac Fibrosis-on-a-Chip for High-Throughput Anti-Fibrotic Drug Screening

Determining sex differences in drug combinations targeting aortic valve myofibroblast activation using an artificial intelligence derived platform

Integration of Different Cardiac Electrophysiological Models into a Single Simulation Pipeline

A computational model predicts sex-specific responses to calcium channel blockers in mammalian mesenteric vascular smooth muscle

Identification of Disease-relevant, Sex-based Proteomic Differences in iPSC-derived Vascular Smooth Muscle

Enhanced drug classification using machine learning with multiplexed cardiac contractility assays

Computational Modeling on Drugs Effects for Left Ventricle in Cardiomyopathy Disease

Integration analysis using bioinformatics and experimental validation on cellular signalling for sex differences of hypertrophic cardiomyopathy

Primary Mouse Aortic Smooth Muscle Cells Exhibit Region- and Sex-Dependent Biological Responses In Vitro

Sex and Tamoxifen confound murine experimental studies in cardiovascular tissue engineering

Network modeling predicts personalized gene expression and drug responses in valve myofibroblasts cultured with patient sera

Cardiovascular disease models: A game changing paradigm in drug discovery and screening

A Biomimetic Cardiac Fibrosis-on-a-Chip As a Visible Disease Model for Evaluating Mesenchymal Stem Cell-Derived Exosome Therapy.

Enhanced Ca2+-Driven Arrhythmogenic Events in Female Patients With Atrial Fibrillation: Insights From Computational Modeling